Skip to Content

Select a date & time

January 2026
Sun Mon Tue Wed Thu Fri Sat
28
29
30
31
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
February 2026
Sun Mon Tue Wed Thu Fri Sat
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
March 2026
Sun Mon Tue Wed Thu Fri Sat
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
April 2026
Sun Mon Tue Wed Thu Fri Sat
29
30
31
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
1
2
Description

mRNA (messenger RNA) screening as candidate for vaccines.


CleaScrip™ Custom mRNA (Low dsRNA)

CleaScrip™ mRNA (via Gentaur) – Practical Advice​

  • When to choose CleaScrip™

  • You work with immune-sensitive systems (primary cells, stem cells, in vivo models).

  • You need low innate immune activation (low dsRNA).

  • You want high translation efficiency without complex downstream cleanup.

  • What to clarify with Gentaur (before ordering)

  • Ask the Gentaur technical representative to review:

  • mRNA length and GC content (impacts yield and integrity)

  • Cap structure (Cap1 standard; alternatives if needed)

  • Poly(A) tail length (default ~100 nt; adjust for stability)

  • Modified bases (e.g. ψU, m5C for reduced immunogenicity)

  • Final concentration & buffer (for transfection or LNP prep)

  • QC package (dsRNA level, integrity, capping efficiency)

  • Design recommendations

  • Prefer codon optimization for mammalian expression.

  • Avoid strong secondary structures at the 5′ UTR.

  • For mRNA >5 kb, confirm expected integrity % in advance.

  • Logistics & support

  • Gentaur handles quotations, lead times, and ordering.

  • A Gentaur technical representative can visit your lab to:

  • Advise on experimental design

  • Compare CleaScrip™ to standard IVT options


  1. Align specs with your delivery method (lipofection, LNP)

  3. Common pitfalls to avoid

  5. Ordering unmodified mRNA for immune-sensitive assays.

  7. Not confirming dsRNA specifications in QC.

  9. Underestimating storage and handling (RNase-free workflow, −80 °C storage).

  11. Best use cases

  13. Proof-of-concept expression studies

  15. Preclinical mRNA workflows


Comparison studies vs standard T7 IVT

Top-notch mRNAs characterized by  Yeasen's low dsRNA levels and exceptional integrity are indispensable for disease research utilizing mRNA tools and the advancement of RNA therapeutics.

https://www.yeasenbio.com/pages/cleascrip%E2%84%A2-mrna-synthesis-low-dsrna

https://www.yeabio.com/pages/cleascrip%E2%84%A2-mrna-synthesis-low-dsrna

Due to the ability of dsRNA to signal through Toll-like receptors TLR3 and RLR-mediated pathways, it is crucial to control the dsRNA content during clinical research. In primary cells and stem cells, the presence of dsRNA-binding receptors will inevitably trigger an immune response. 

Yeasen offers exceptional control over the dsRNA content in mRNA.

In conventional mRNA synthesis services do not include a step for dsRNA removal. Adding this step increases costs, making the product more expensive. Typically, mRNA is categorized into RUO (Research Use Only) grade and preclinical grade, with dsRNA content being a key distinguishing factor. Yeasen Biotechnology, through collaboration with third parties and the use of the CleaScrip™ T7 RNA polymerase, can provide mRNA with ultra-low dsRNA content for drug or vaccine development scientists from the outset. This enables researchers to access near-clinical-grade quality mRNA at a lower cost from the very beginning.

mRNA

Our exclusive mRNA manufacturing process relies on CleaScrip™ T7 RNA Polymerase, enabling the production of high-quality mRNAs with remarkably low dsRNA content (approximately 1/100000), coupled with numerous customizable features.

 

A Comprehensive Solution for CleaScrip™ mRNA Production

Our mRNA production service simplifies your process from protein sequence to LNP delivery. Our expert team guarantees the excellence and expression effectiveness of your mRNA, offering a seamless, all-in-one solution.

 mRNA holds several unique properties that are advantageous in the development of new therapies, including highly localized expression patterns, rapid development time, and a high degree of safety as a non-genome editing substrate for therapies.


Yeasen's custom mRNA production with superior purity, 3 month timeline.





Yeasen mRNA services can help to streamline the vaccine and drug development process and accelerate the translation of targets into practical therapies by helping to smooth the transition from early research and development to GMP mRNA manufacturing.


Request A Quote from Gentaur

Contact Our Expert Lieven Gevaert Bio-ir. RUG 1996

https://www.yeasenbio.com/pages/distributors


  1. Superior mRNA Quality
  2. Built-in CE test to guarantee mRNA quality
  3. Guaranteed LNP particle size and uniformity
  4. Comprehensive QC tests panel